دورية أكاديمية
Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
| العنوان: | Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial |
|---|---|
| المؤلفون: | Tina Cascone, Gozde Kar, Jonathan D. Spicer, Rosario García-Campelo, Walter Weder, Davey B. Daniel, David R. Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin H. Yau, Alexander I. Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R. Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M. Forde |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Cancer, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Clinical Trial Results, Immunotherapy, Lung Cancer, Translational Research |
| الوصف: | Additional details on safety endpoints. Supplementary tables: 1, Representativeness of study participants; 2, Efficacy summary; 3, Adverse events occurring in ≥10% of patients; 4, Treatment-related adverse events occurring in ≥5% of patients; 5, Adverse events of special or potential interest; 6, Baseline biomarker association with response. Supplementary figures: 1, Mechanism of action for each study drug; 2, Violin plots with median % residual viable tumor cells; 3, Additional immunohistochemistry biomarker to major pathological response; 4, Calculation of gene signatures associated with tertiary lymphoid structure (TLS) formation; 5, Changes in immune cell populations by deconvolution; 6, Stool microbiome richness and diversity; 7, ctDNA dynamics. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | https://figshare.com/articles/journal_contribution/Supplementary_Appendix_from_Neoadjuvant_Durvalumab_Alone_or_Combined_with_Novel_Immuno-Oncology_Agents_in_Resectable_Lung_Cancer_The_Phase_II_NeoCOAST_Platform_Trial/24473995Test |
| DOI: | 10.1158/2159-8290.24473995.v1 |
| الإتاحة: | https://doi.org/10.1158/2159-8290.24473995.v1Test https://figshare.com/articles/journal_contribution/Supplementary_Appendix_from_Neoadjuvant_Durvalumab_Alone_or_Combined_with_Novel_Immuno-Oncology_Agents_in_Resectable_Lung_Cancer_The_Phase_II_NeoCOAST_Platform_Trial/24473995Test |
| حقوق: | CC BY |
| رقم الانضمام: | edsbas.E9F7C055 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1158/2159-8290.24473995.v1 |
|---|